Omada Health (OMDA)

NASDAQ • Healthcare

$22.77

+$0.48 (+2.2%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$21.86 - $22.97

Avg. Volume (3M)1.3M

Market Cap$1.3B

P/E Ratio335.3

52 Week Range

$10.28$26.92

Next EarningsIn 62 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$87.8M100%

Gross Profitminus cost of goods$63.7M73%

Operating Incomeminus R&D and overhead$3.5M4%

Net Incomeminus taxes and the rest$5.2M6%

In plain terms: out of every $100 in revenue, Omada Health keeps $6 as net profit.

Fundamentals & Financials

Revenue (TTM)

$309.7M

Net Income (TTM)

$4.3M

EPS (TTM)

$0.068

ROA (TTM)

1.31%

Current Ratio

3.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+10.0%Q3 2025-$0.09

+40.0%Q4 2025-$0.06

+333.3%Q1 2026$0.13

+112.5%Q2 2026$0.01

+141.2%Q3 2026$0.15

Nov 5

in 62 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Omada Health

Omada Health, listed on the NASDAQ Global Market as OMDA, provides digital healthcare services centered on chronic-condition management and virtual support in the United States. The company operates in healthcare information services and generated $260.2 million of revenue in FY2025.

Name

Omada Health

CEO

Sean Duffy

Website

www.omadahealth.com

Industry

Healthcare

Employees

946

Today's Snapshot

AI-generated

The day ended with OMDA 2.1% higher at 22.77, outperforming a weaker sector.

Trading Volume

Below 10d avg (1.0M)

877.3K

vs S&P 500 Today

Outperforming Market

+2.57%

Updated: September 4, 2026 at 20:20 UTC

Technical Indicators

3 Buy3 Neutral2 Sell

OMDA reads as cautiously constructive, with an ADX indicating a developing trend and on‑balance volume confirming buying interest. Short-term momentum indicators are mixed and the CCI is deeply oversold, yet price sits above several longer-term moving averages, including the 50- and 200-day, which supports a bullish backdrop. Volatility is elevated, creating wider intraday swings around the pivot close to 22.33, and the MACD is mildly positive. Technical takeaway: Buy.

All signals